CytomX Therapeutics (CTMX) – Investment Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of CytomX Therapeutics (NASDAQ: CTMX) recently:

• 1/20/2026 – CytomX Therapeutics had its price target raised by analysts at Piper Sandler from $6.50 to $10.00. They now have an “overweight” rating on the stock.
• 1/20/2026 – CytomX Therapeutics is now covered by analysts at Guggenheim. They set a “buy” rating and a $10.00 price target on the stock.
• 1/20/2026 – CytomX Therapeutics had its price target raised by analysts at Barclays PLC from $6.00 to $8.00. They now have an “overweight” rating on the stock.
• 1/20/2026 – CytomX Therapeutics is now covered by analysts at Guggenheim. They set a “buy” rating and a $10.00 price target on the stock.

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.